fbpx

News & Press


FDA Approves New Targeted Therapy Combination (Vemurafenib and Cobimetinib) to Treat Advanced Melanoma

November 10, 2015

Today, the FDA approved the targeted therapy combination of vemurafenib (Zelboraf®) with cobimetinib (Cotellic) for people who have advanced or metastatic melanoma and who test positive for the genetic mutation, BRAF V600. Statement from Tim Turnham, E …



Washington, D.C. Community Combats Melanoma at 7th Annual Wings of Hope Gala

November 6, 2015

Washington, D.C. – On Saturday, November 7th, the Washington, D.C. melanoma community will come together to honor those who have been impacted by melanoma and raise funds to support the search for new and better treatment options at the 7th annual DC W …



#CUREOM Unite! – Thank You!

October 30, 2015

The results are in and #CUREOM Unite! was a tremendous success! Thank you to everyone who gave so generously to this campaign to further patient-centered ocular melanoma (OM) research! Dear Friends,   As of October 15, 2015, the #CUREOM Unite! cam …



FDA Approves First New Adjuvant Treatment for Stage III Melanoma Patients in 20 Years

October 27, 2015

Statement from Tim Turnham, Executive Director, Melanoma Research Foundation   Washington, D.C.—Today the Food and Drug Administration (FDA) approved ipilimumab (Yervoy) for use as a way to lower the risk of recurrence for melanoma patients …



FDA Approves Talimogene Laherparepvec (T-VEC) for Advanced Melanoma

October 27, 2015

Today the FDA approved Amgen’s drug, Imlygic (Talimogene Laherparepvec or T-VEC), for the treatment of unresectable Stage IIIB, IIIC or IV metastatic melanoma, bringing a novel immunotherapy to people with advanced melanoma, many of whom have limited t …